Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that cucurbitacin cream reduced FGF18 levels and accelerated hair follicle transition to the anagen phase in mice, suggesting its potential as a treatment for hair regeneration.

In this study, tacrolimus-based treatment was found to result in fewer overall side effects compared to cyclosporine among Yemeni kidney transplant patients, although tacrolimus was associated with a higher incidence of diabetes.

In this study, the researchers observed that inducing and then withdrawing β-catenin expression in a bigenic mouse model caused reversible changes in skin morphology, indicating dependence on β-catenin signaling.

This article reviews new drug therapies for endocrine disorders, discussing specific treatments such as trilostane for hyperadrenocorticism and various insulins for diabetes mellitus, but it reports no new clinical findings.

Alopecia areata often recurs after treatment with diphenylcyclopropenone.

In this study, DPHC from the brown alga Ishige okamurae demonstrated potential to prevent androgenic alopecia by inhibiting hair loss and promoting hair growth through multiple cellular mechanisms.

This study observed that while dexamethasone-cyclophosphamide pulse therapy is relatively free from hypertension and diabetes compared to conventional steroids in pemphigus patients, it frequently causes generalized weakness and flushing.

This study presents an algorithm that may help physicians diagnose female hair loss by synthesizing patient history, clinical examination, and various diagnostic tests.

This study reported that newly synthesized nonsteroidal compounds were effective at inhibiting prostatic 5 alpha reductase isozyme 2, especially the compound with an N, N-diisopropylcarbamoyl substituent, suggesting potential for treating benign prostatic hyperplasia.

This review examines melatonin's role in managing PCOS and its potential to improve hormonal balance, oxidative stress, sleep quality, and mood, but reports no new clinical results.

This case report describes a 10-year-old terrier with pituitary-dependent hyperadrenocorticism successfully treated with mitotane.

This study found that higher concentrations of topical diphenylcyclopropenone, especially when prepared with acetone, showed better stability over 6 months compared to lower concentrations.

This case report describes a woman diagnosed with Cronkhite-Canada syndrome whose gastrointestinal symptoms and alopecia improved significantly after systemic prednisone treatment, with no recurrence four years after a second treatment course.

In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.

This study found that ferulic acid significantly reduced seizure susceptibility and depression-like behaviors in a mouse model of catamenial epilepsy, likely by restoring hormone levels and neurotransmitter activity.

This study found that the cosmetic olfactory receptor agonist cyclohexyl salicylate may stimulate hair growth and expand stem cell progeny, suggesting potential as a cosmetic adjuvant for hair loss.

This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.

This study in rats found that a new hydroxypropyl-β-cyclodextrin formulation of minoxidil reduced the adverse cardiovascular and proliferative effects seen with traditional minoxidil solutions.

In this case report, a 23-year-old man with alopecia universalis applied topical cyclosporine for several months, resulting in noticeable hair regrowth.

This case series reports three cats diagnosed with hypersomatotropism due to GH-secreting pituitary adenomas without concurrent diabetes mellitus, highlighting the potential for underdiagnosis in non-diabetic cats.

In this study, severe hair loss occurred in PKC epsilon transgenic mice treated with DFMO during skin tumor prevention, highlighting a link between polyamine biosynthesis, hair follicle maintenance, and metastasis suppression.

In this study, a synthetic antagonist of the p75 neurotrophin receptor was found to significantly inhibit hair follicle regression in murine skin cultures, suggesting a potential role in treating hair disorders characterized by premature catagen entry.

This review analyzes the mnemonic MY PCOS, exploring diagnosis and treatment strategies for the metabolic, cosmetic, and reproductive complications of polycystic ovary syndrome, without reporting new clinical findings.

This study found that oral cyclosporine was more effective than betamethasone minipulse therapy for treating Alopecia Areata, with more patients in the cyclosporine group showing excellent and good responses compared to the betamethasone group.

This case report described a one-year-old male husky dog with severe itching and skin lesions caused by Demodex canis, where treatment with Nexgard® and other supportive therapies over two weeks improved the dog's condition, indicating Nexgard® as a viable option for managing canine demodicosis.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

This case report describes the topical application of cyclosporine in a man with alopecia universalis, which showed hair regrowth after 10 months of daily use, except where limited by a congenital nevus.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.